Maya Frutiger
Head of Corporate Communications
maya.frutiger@us.sumitomo-pharma.com
News Releases
Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 15, 2023
Gedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland GmbH ('SMPS') today announce that the Committee for Medicinal Products for...
-
Sep 11, 2023
–Vibegron Met Both Co-Primary Endpoints Demonstrating Statistically Significant Reductions in Daily Micturition and Urgency Episodes, Compared to Placebo at Week 12– –Vibegron Met All...
-
Jul 31, 2023
July 31, 2023 — Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President, and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) and Otsuka...
-
Jul 10, 2023
CAMBRIDGE, Mass., July 10, 2023 /PRNewswire/ — Sumitomo Pharma America, Inc. (SMPA), as previously announced on April 3, 2023, is pleased to share it has successfully launched its operations in...
-
Apr 26, 2023–Approximately 7.5 Million People in The U.S. Are Living with Generalized Anxiety Disorder (GAD) 1,2
MARLBOROUGH, Mass. & PRINCETON, N.J., April 26, 2023 8:00 am (BUSINESS WIRE) — Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka)...
-
Apr 3, 2023
NEW YORK., April 3, 2023 – Sumitovant Biopharma Ltd. (“Sumitovant”) announced today that its parent company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”) will combine its wholly owned...
-
Mar 10, 2023
NEW YORK and BASEL, Switzerland, March 10, 2023 /PRNewswire/ — Sumitovant Biopharma Ltd. (“Sumitovant”) and Myovant Sciences Ltd. (“Myovant”) announced today that Sumitovant has...
-
Jan 19, 2023•Urovant Sciences, Inc., and Holly Robinson Peete Collaborate to Bring Awareness to Overactive Bladder (OAB) Symptoms and Management Options as Part of the Time To Go™ Campaign
IRVINE, Calif. & ZUG, Switzerland – January 19, 2023 – Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma, Ltd., today announced its partnership with actress and overactive...
-
Nov 14, 2022•Urovant Sciences, Inc and Thinx, Inc Form a Unique Partnership Designed to Educate People Living with The Symptoms of Overactive Bladder (OAB)
IRVINE, Calif. & BASEL, Switzerland – November 14, 2022 – Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced the launch of Time To GoTM today, a multi-channel...
-
Nov 1, 2022First Trial to Study a Trace Amine-Associated Receptor 1 (TAAR1) Agonist in Major Depressive Disorder (MDD)
PRINCETON, M.J. & MARLBOROUGH, MASS. – December 1, 2022 – Otsuka Pharmaceutical Development & Commercialization, Inc.(Otsuka) and Sunovion Pharmaceuticals Inc. (Sunovion) today announced that...
-
Aug 5, 2022•Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment
BASEL, Switzerland and NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has...
-
Jul 5, 2022•Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the European Economic Area, UK, and Switzerland.
Basel, Switzerland, and Castres, France – July 5, 2022 — Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., and Pierre Fabre Médicament today announced they have...
-
Jun 16, 2022
BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2...
-
Apr 22, 2022
Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced today plans to develop a Good Manufacturing Practice (GMP)-compliant...
-
Feb 9, 2022
MARLBOROUGH, Mass. & PRINCETON, N.J., February 09, 2022 08:00 am (BUSINESS WIRE) — Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc....
-
Oct 8, 2021•RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia
CAMBRIDGE, Mass. & BASEL, Switzerland, October 8, 2021 (GLOBE NEWSWIRE) – Enzyvant today announced the U.S. Food and Drug Administration (FDA) approval of RETHYMIC® (allogeneic processed thymus...
-
Sep 30, 2021-Companies to advance four promising Sunovion compounds for people living with serious neuropsychiatric conditions-
MARLBOROUGH, Mass. & OSAKA, Japan & TOKYO, Japan--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion),its parent company Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Dainippon Pharma) and...
-
Jun 29, 2021•Co-promotion extends sales and market access efforts to reach primary care physicians who treat OAB patients
IRVINE, Calif. & BASEL, Switzerland & MARLBOROUGH, Mass., June 29, 2021 at 9:00 AM EDT (BUSINESS WIRE)– Urovant Sciences, Inc. and Sunovion Pharmaceuticals Inc. today announced the launch of...
-
May 26, 2021•In the Phase 3 LIBERTY 1 and LIBERTY 2 studies, MYFEMBREE demonstrated 72.1% and 71.2% response rates in menstrual blood loss (MBL) at Week 24, with MBL reductions of 82.0% and 84.3% from baseline
BASEL, Switzerland and NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has...
-
Apr 12, 2021•SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 years
BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3...
-
Apr 2, 2021Nationwide availability gives healthcare providers and patients a new treatment option
IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)– Urovant Sciences, a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today...
-
Mar 29, 2021•If approved, relugolix would be the first and only oral androgen deprivation therapy for advanced prostate cancer in Europe
BASEL, Switzerland, March 29, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines...
-
Feb 17, 2021•LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline
NEW YORK, LONDON, February 17, 2021 (GLOBE NEWSWIRE) — Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the New England Journal of...
-
Feb 16, 2021•Six women reflect on their period experiences and journeys to self-advocacy in new video series
RED BANK, N.J. and BASEL, Switzerland, Feb. 16, 2021 (GLOBE NEWSWIRE) — HealthyWomen, the nation’s leading independent, nonprofit health information source for women, and Myovant Sciences...
-
Jan 5, 2021
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™...